Medidata Rave RCM is a mobile document management application for clinical trial professionals to access and approve regulated content on iOS and Android.
Product velocity
Dormant
Daily rank 🇺🇸
—
Medical
Sentiment
2.0
54 reviews
Nemesis
Fragmented field
The App DNA
What makes this app unique?
Users hire the app to maintain 21 CFR Part 11 compliance while working in the field, ensuring that document workflows continue without requiring a laptop.
For Clinical trial professionals, site managers, and auditors requiring secure, mobile access to regulated trial documentation.
What does it look like?
Key features
Validation and security protocols for regulated content management
Document approval and comment review process
Biometric security for task approval
How much does it cost?
The app functions as a free mobile extension for existing B2B enterprise customers, with no direct consumer-facing pricing.
Velocity
Dormant developmentUX improvementsplatform expansionShow more...
The development momentum is classified as zombie due to the lack of any release activity for over four years. The most recent release occurred in March 2022, and there is no evidence of ongoing maintenance or feature updates. The historical data indicates a long-term cessation of development activity for this application.
Who built it?
User Sentiment
What do users think recently?
Fresh user feedback skews upset. Users appreciate regulatory document signing features provide time-saving utility for clinical professionals during field work.
How are ratings & reviews evolving?
What users say, by theme
- Regulatory document signing features provide time-saving utility for clinical professionals during field work
- Persistent application crashes and loading failures prevent field agents from completing daily repossession tasks
33 of 33 recent reviews analyzed · high confidence · Upset overall
Read the full review analysisCompetition
Competitive landscape for Medidata Rave RCM
How's the Medical market?
Medidata Rave RCM occupies a niche in the regulated clinical trial market, maintaining a 1.94 rating on Android despite its role as a mandatory tool for Medidata enterprise users.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Medidata Rave RCM
Where is it heading?
The regulated content management market is shifting toward offline-first architectures to ensure productivity in connectivity-constrained environments. Medidata Rave RCM remains exposed due to its reliance on stable network conditions, so the PM must address these synchronization failures to prevent enterprise clients from seeking more reliable alternatives.
- Persistent crashes during core tasks erode user trust, which compounds the rating drag already visible on the Android platform.
- Synchronization errors between the app and backend lead to operational compliance risks, threatening the app's value as a regulated tool.
The SWOT
- 21 CFR Part 11 compliance functions as a B2B distribution moat
- Integration into clinical trial workflows creates high switching costs
- Implement offline-first synchronization to match ownCloud
- Add real-time team collaboration tools to compete with kDrive
Next best moves
Rebuild photo upload and sync logic because crashes are the top complaint → improve Android stability
+ 1 more prioritized moveThe counter-intuitive read
The app's low rating is not a failure…
Read the full takeFeature gaps
Offline-first synchronization (available in ownCloud but absent here) +1
Since the last report: The product focus shifted from addressing navigation friction to resolving critical stability and synchronization failures, while the competitive benchmarking moved toward offline-first and utility-focused document tools.
Bottom line
Medidata Rave RCM holds a critical position in clinical trial workflows, but the current Android instability risks operational compliance, so the PM must prioritize backend stability over new feature expansion to protect the B2B user base.
Unlock 3 critical frictions, 2 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeReport last updated